全文获取类型
收费全文 | 6685篇 |
免费 | 1076篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 817篇 |
妇产科学 | 483篇 |
基础医学 | 200篇 |
口腔科学 | 87篇 |
临床医学 | 509篇 |
内科学 | 211篇 |
皮肤病学 | 44篇 |
神经病学 | 35篇 |
特种医学 | 169篇 |
外国民族医学 | 1篇 |
外科学 | 523篇 |
综合类 | 277篇 |
预防医学 | 299篇 |
眼科学 | 22篇 |
药学 | 259篇 |
12篇 | |
中国医学 | 48篇 |
肿瘤学 | 3757篇 |
出版年
2024年 | 36篇 |
2023年 | 260篇 |
2022年 | 252篇 |
2021年 | 359篇 |
2020年 | 516篇 |
2019年 | 634篇 |
2018年 | 619篇 |
2017年 | 471篇 |
2016年 | 284篇 |
2015年 | 369篇 |
2014年 | 494篇 |
2013年 | 740篇 |
2012年 | 365篇 |
2011年 | 389篇 |
2010年 | 328篇 |
2009年 | 318篇 |
2008年 | 289篇 |
2007年 | 200篇 |
2006年 | 178篇 |
2005年 | 108篇 |
2004年 | 80篇 |
2003年 | 50篇 |
2002年 | 51篇 |
2001年 | 45篇 |
2000年 | 40篇 |
1999年 | 32篇 |
1998年 | 30篇 |
1997年 | 28篇 |
1996年 | 29篇 |
1995年 | 23篇 |
1994年 | 18篇 |
1993年 | 14篇 |
1992年 | 15篇 |
1991年 | 7篇 |
1990年 | 5篇 |
1989年 | 7篇 |
1988年 | 10篇 |
1987年 | 5篇 |
1986年 | 2篇 |
1985年 | 8篇 |
1984年 | 23篇 |
1983年 | 13篇 |
1982年 | 8篇 |
1981年 | 8篇 |
1980年 | 14篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1976年 | 3篇 |
1974年 | 1篇 |
排序方式: 共有7792条查询结果,搜索用时 156 毫秒
991.
992.
Ryan Hirschfeld Jennifer J.G. Welch Douglas J. Harrison Robin Kremsdorf Anjulika Chawla 《Pediatric blood & cancer》2017,64(10)
We report two infants with infantile fibrosarcoma (IFS) complicated by severe hypercalcemia. Assessment demonstrated suppressed parathyroid hormone and 1,25‐dihydroxyvitamin D levels with elevated circulating levels of parathyroid hormone related protein, indicating the diagnosis of humoral hypercalcemia of malignancy (HHM). HHM is a paraneoplastic syndrome rarely associated with pediatric malignancies. Hypercalcemia manifested clinically with neurologic symptoms and soft tissue calcium deposition and required aggressive management with intravenous fluids, diuretics, and supplemental electrolytes. Following treatment with neoadjuvant chemotherapy, serum calcium levels precipitously declined requiring calcium repletion. These cases highlight the improvement of hypercalcemia secondary to HHM following chemotherapy. 相似文献
993.
994.
995.
The rising cost of pharmaceuticals and, in particular, cancer drugs has made headline news in recent years. Several factors contribute to increasing costs and the burden this places on the health care system and patients. Some of these factors include costly cancer pharmaceutical research and development, longer clinical trials required to achieve drug approval, manufacturing costs for complex compounds, and the economic principles surrounding oncology drug pricing. Strategies to control costs have been proposed, and some have already been implemented to mitigate cancer drug costs such as the use of clinical treatment pathways and tools to facilitate cost discussions with patients. In this article, we briefly review some of the potential factors contributing to increasing cancer pharmaceutical costs and interventions to mitigate costs, and touch on the role of health care providers in addressing this important issue. 相似文献
996.
Oncology Drug Dosing in Gilbert Syndrome Associated with UGT1A1: A Summary of the Literature
下载免费PDF全文
![点击此处可从《Pharmacotherapy》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Gilbert syndrome (GS) is a hereditary condition that affects ~10% of the population. It is characterized by intermittent, unconjugated hyperbilirubinemia in the absence of hepatocellular damage and hemolysis. Although GS is often described as a benign laboratory finding, it may alter drug metabolism by decreasing the ability to conjugate drugs. Genetic polymorphisms, specifically the UGT1A1*28 allele, may reduce glucuronidation by 30% that severely impacts the ability to metabolize certain medications. Antineoplastic agents used in oncologic settings have toxic side effects, and alterations in metabolism may result in severe or even life‐threatening toxicities. Many of the drug monographs provided by manufacturers contain dose adjustment parameters for hepatic function, using serum bilirubin as a surrogate marker. However, in patients with GS, hepatic function remains normal in the setting of hyperbilirubinemia, and scant literature is available to provide guidance on empirical dosage adjustment. In this review, we conducted a literature search of routinely used oncology medications and assessed the need for empirical dose adjustments in the setting of GS. 相似文献
997.
Hypofractionated versus conventionally fractionated radiotherapy for ductal carcinoma in situ (DCIS) of the breast
下载免费PDF全文
![点击此处可从《Journal of Medical Imaging and Radiation Oncology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
998.
999.
1000.
Patient preferences on the integration of complementary therapy with conventional cancer care
下载免费PDF全文
![点击此处可从《Asia-Pacific Journal of Clinical Oncology》网站下载免费的PDF全文](/ch/ext_images/free.gif)